A recent New York Post article discussed a new regulatory advancement for MDMA. The drug, commonly known as ecstasy or molly, is a psychoactive drug primarily known for recreational use. However, years of research and clinical trials have shown the drug can be an effective treatment for post-traumatic stress disorder (PTSD). The Multidisciplinary Association for Psychedelic Studies (MAPS) announced they have received “expanded access” approval from the FDA to continue research that could likely lead to the legalization of MDMA for medical purposes.